Please try another search
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer’s disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer’s disease; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Anders Waas | 64 | 2018 | Director |
Carol Routledge | - | 2018 | Director |
Clas Malmestrom | 56 | 2015 | Director |
Lena Degling Wikingsson | 60 | 2020 | Independent Director |
Per-Goran Gillberg | - | 2020 | Independent Director |
Jesper Dahlberg | - | - | Deputy Board Member |
Anders Blom | 54 | 2021 | Director |
Anders Sandberg | 52 | 2011 | Chief Scientific Officer |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review